ANAB
AnaptysBio, Inc.
There isn't enough reported data to score ANAB yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ANAB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
ANAB's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ANAB PE Valuation
ANAB has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 5.3x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ANAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ANAB to return to profit, with revenue growing. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ANAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.01 | — |
| Q1 2026 | -$1.02 | +$3.74 |
| Q4 2025 | -$0.46 | +$4.66 |
| Q3 2025 | -$2.73 | +$3.35 |
| Q2 2025 | -$4.39 | +$1.96 |
| Q1 2025 | -$4.76 | +$1.38 |
| Q4 2024 | -$5.12 | +$0.96 |
| Q3 2024 | -$6.08 | -$0.66 |
| Q2 2024 | -$6.35 | -$1.16 |
ANAB is still losing money, but far less than before: $1.02 per share over the past year, against $6.35 at its worst in mid-2024.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ANAB on earnings quality, reporting a profit while its opponent remains loss making.
ANAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.3M | -60% |
| Q1 2026 | $25.6M | -8% |
| Q4 2025 | $108.2M | +151% |
| Q3 2025 | $76.3M | +154% |
| Q2 2025 | $22.3M | +103% |
| Q1 2025 | $27.8M | +287% |
| Q4 2024 | $43.1M | +379% |
| Q3 2024 | $30M | +805% |
ANAB has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +20 points |
| Q1 2026 | -136% | -36 points |
| Q4 2025 | 62% | +84 points |
| Q3 2025 | 45% | +121 points |
| Q2 2025 | -118% | +250 points |
| Q1 2025 | -99% | +489 points |
| Q4 2024 | -22% | +446 points |
| Q3 2024 | -76% | +1061 points |
ANAB has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
ANAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | +$17.8M |
| Q1 2026 | -$25.9M | -$15.2M |
| Q4 2025 | $98M | +$164.9M |
| Q3 2025 | -$27.4M | -$17.2M |
| Q2 2025 | -$40.3M | -$18.9M |
| Q1 2025 | -$10.7M | +$26.5M |
| Q4 2024 | -$66.9M | -$32.3M |
| Q3 2024 | -$10.1M | +$26.5M |
ANAB's free cash flow has turned positive after six years mostly in the red: $35M over the past year.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ANAB on cash flow, with more consistent year-over-year improvement.
ANAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +22% | +6.4M shares |
| 1 year | +22% | +6.3M shares |
| 3 years | +32% | +8.4M shares |
| 5 years | +28% | +7.7M shares |
| Available history | +30% | +8M shares |
ANAB has 35M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $3.4M |
| Q3 2025 | $9.7M |
| Q2 2025 | $51.1M |
| Q1 2025 | $4.4M |
| Q4 2024 | $456,000 |
| Q3 2024 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ANAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ANAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.0x | Net Cash |
| Q4 2025 | -4.9x | Net Cash |
| Q3 2021 | -40.6x | Net Cash |
ANAB has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ANAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 21.4 | Neutral |
ANAB's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ANAB PE vs Healthcare Sector
| Metric | ANAB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANAB has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ANAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.9 | 0.3% below |
| 20 week MA | $53.7 | 11% below |
| 50 week MA | $47.7 | 0.1% above |
| 100 week MA | $31.5 | 52% above |
| 200 week MA | $23.5 | 103% above |
ANAB has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ANAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.2 | $14.8 | +33% |
| 2021 | $14.8 | $24.7 | +67% |
| 2022 | $24.7 | $19.5 | -21% |
| 2023 | $19.5 | $14.3 | -27% |
| 2024 | $14.3 | $8.69 | -39% |
| 2025 | $8.69 | $33.4 | +284% |
| 2026 YTD | $33.4 | $47.8 | +43% |
ANAB has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.